Hogan Lovells advises March Biosciences in closing oversubscribed US$28.4 million Series A financing

Advising firms

The announcement does not name individual lawyers.

Want co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.

Stated terms

Stated value

USD 28.4m (US$28.4 million)

What the figure measures

Issue size

Client

March BiosciencesIssuer

Counterparties

Mission BioCapital (Investor)
4BIO Capital (Investor)
KdT Ventures (Investor)
Alexandria Venture Investments (Investor)
Volnay Therapeutics (Investor)
Modi Ventures (Investor)
Mansueto Investments (Investor)